KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Net Margin: 2020-2025

Historic Net Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -3,135.32%.

  • Recursion Pharmaceuticals' Net Margin fell 276786.00% to -3,135.32% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,637.81%, marking a year-over-year decrease of 105830.00%. This contributed to the annual value of -788.02% for FY2024, which is 5203.00% down from last year.
  • Recursion Pharmaceuticals' Net Margin amounted to -3,135.32% in Q3 2025, which was down 250.62% from -894.23% recorded in Q2 2025.
  • Recursion Pharmaceuticals' Net Margin's 5-year high stood at -367.46% during Q3 2024, with a 5-year trough of -3,935.46% in Q4 2024.
  • Moreover, its 3-year median value for Net Margin was -853.88% (2023), whereas its average is -1,274.23%.
  • In the last 5 years, Recursion Pharmaceuticals' Net Margin soared by 2,938,181bps in 2021 and then plummeted by 308,158bps in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Margin (Quarterly) stood at -2,564.55% in 2021, then soared by 211,864bps to -445.91% in 2022, then plummeted by 40,797bps to -853.88% in 2023, then slumped by 308,158bps to -3,935.46% in 2024, then tumbled by 276,786bps to -3,135.32% in 2025.
  • Its last three reported values are -3,135.32% in Q3 2025, -894.23% for Q2 2025, and -1,373.26% during Q1 2025.